TALEN-Mediated Genomic Engineering of Neural Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for genomic engineering of human neuronal stem cells, particularly for multiplexed knock-in or transfer of large DNA fragments, are limited, hindering their therapeutic applications in neurodegenerative disorders such as Parkinson's disease, where sufficient cell numbers and efficient differentiation are needed for effective treatment.
Innovation Solution
The use of recombinant polynucleotide-binding polypeptides and fusion proteins, specifically TALENs, to target and modify genomic DNA in neuronal stem cells, enabling precise insertion of donor polynucleotides into safe harbor loci, facilitating homologous recombination and efficient gene editing, and promoting cell differentiation and therapeutic protein expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional gene targeting methods are used in human neuronal stem cells, then existing techniques can be applied, but multiplexed knock-in or transfer of large DNA fragments cannot be achieved
Solution Approach 1:
The patent combines multiple gene editing functions into a single integrated system using TALEN proteins that can simultaneously perform homology-directed repair at multiple loci. The donor polynucleotide contains multiple transgenes flanked by homology arms that target specific safe harbor loci, enabling multiplexed knock-in of large DNA fragments in one operation.
Solution Approach 2:
The patent introduces TALEN proteins as intermediary molecules that facilitate precise genome editing. These proteins bind to specific DNA sequences at safe harbor loci and mediate the insertion of donor polynucleotides through homology-directed repair, enabling controlled transfer of large DNA fragments without relying on conventional limiting methods.
2Productivity
If sufficient cell numbers are produced for therapy, then treatment effectiveness improves, but current methods do not efficiently generate the required cell populations
Solution Approach 1:
The patent performs preliminary genome engineering in neuronal stem cells before differentiation, introducing therapeutic transgenes at safe harbor loci using TALEN-mediated homology-directed repair. This preliminary action ensures that sufficient numbers of genetically engineered cells can be produced and differentiated into therapeutic neural cells for treatment.
3Manufacturing precision
If precise gene editing is achieved, then therapeutic accuracy improves, but existing methods lack the precision required for safe harbor locus integration
Solution Approach 1:
The patent applies local quality by targeting specific safe harbor loci (such as PPP1R12C/AAVS1 and hRosa26) with TALEN proteins that have high sequence specificity. The donor polynucleotide contains homology arms matched to these specific loci, ensuring precise integration at the intended site while avoiding off-target effects.
4Productivity
If efficient cell differentiation is achieved, then therapeutic application effectiveness improves, but current engineered cells do not differentiate efficiently
Solution Approach 1:
The patent performs preliminary genome engineering at the stem cell stage before differentiation, introducing therapeutic transgenes that can be expressed during subsequent differentiation. This ensures that the genetic modifications are in place before the cells are differentiated into therapeutic neural cells, improving overall differentiation efficiency and therapeutic applicability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for robust and efficient modification of neuronal stem cells, enabling the production of sufficient therapeutic cells for treating neurodegenerative disorders by ensuring precise gene editing and effective cell differentiation, thereby addressing the limitations of existing technologies.
Implementation Method 1
The complementary overhangs facilitate homologous recombination of the donor polynucleotide with the cleaved genomic DNA, thereby introducing the polynucleotide into the genome of the NSC
Implementation Method 2
introducing into the cell a first TALEN with a DNA-binding domain specific for a DNA sequence upstream of a genomic sequence of interest and a second TALEN with a DNA-binding domain specific for a DNA sequence downstream from the genomic sequence of interest, whereby the TALEN cleaves the genomic DNA
Data Source
AI summary
Described herein are recombinant polynucleotide-binding polypeptides, recombinant fusion proteins made with the described polynucleotide-binding polypeptides, methods of using the described recombinant polynucleotide-binding polypeptides and recombinant fusion proteins to modify genomic DNA of cells and, in some embodiments, create recombinant cells. Methods are also provided herein for genetically modifying a neuronal stem cell. Methods are also provided for treating a neurological disorder in a subject that include the administration of genetically modified neuronal stem cells produced by the methods disclosed herein.